Cargando…

Alpha-1-antitrypsin interacts with gp41 to block HIV-1 entry into CD4+ T lymphocytes

BACKGROUND: Study of a clinic case reveals that alpha-1-antitrypsin (AAT) deficiency is related to CD4+ T cell count decline and AIDS progression, suggesting that AAT might be an endogenous inhibitor of HIV/AIDS. Previous study shows that AAT inhibits HIV-1 replication in infected host cells and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xueyuan, Liu, Zhu, Zhang, Jun, Adelsberger, Joseph W., Yang, Jun, Burton, Gregory F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966588/ https://www.ncbi.nlm.nih.gov/pubmed/27473095 http://dx.doi.org/10.1186/s12866-016-0751-2

Ejemplares similares

Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket
por: Yu, Fei, et al.
Publicado: (2013)

Striking HIV-1 Entry by Targeting HIV-1 gp41. But, Where Should We Target?
por: Teixeira, Cátia, et al.
Publicado: (2016)

gp41: HIV's shy protein
por: Zwick, Michael B, et al.
Publicado: (2004)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

N-Substituted Pyrrole Derivative 12m Inhibits HIV-1 Entry by Targeting Gp41 of HIV-1 Envelope Glycoprotein
por: Qiu, Jiayin, et al.
Publicado: (2019)

Neutralizing Antibodies Targeting HIV-1 gp41
por: Caillat, Christophe, et al.
Publicado: (2020)

Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41
por: Yan, Hongxia, et al.
Publicado: (2022)

Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
por: Callea, Francesco, et al.
Publicado: (2018)

Fejerlectin, a Lectin-like Peptide from the Skin of Fejervarya limnocharis, Inhibits HIV-1 Entry by Targeting Gp41
por: Xiong, Weichen, et al.
Publicado: (2021)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

Alpha-1 Antitrypsin as a Therapeutic Agent for Conditions not Associated with Alpha-1 Antitrypsin Deficiency
por: Wanner, Adam
Publicado: (2015)

Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface
por: Torrents de la Peña, Alba, et al.
Publicado: (2021)

HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor
por: Bashir, Tahir, et al.
Publicado: (2015)

Membrane topology analysis of HIV-1 envelope glycoprotein gp41
por: Liu, Shujun, et al.
Publicado: (2010)

Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
por: Petrache, Irina, et al.
Publicado: (2009)

The Conserved Residue Arg46 in the N-Terminal Heptad Repeat Domain of HIV-1 gp41 Is Critical for Viral Fusion and Entry
por: Wang, Xiaoyi, et al.
Publicado: (2012)

SVIP regulates Z variant alpha-1 antitrypsin retro-translocation by inhibiting ubiquitin ligase gp78
por: Khodayari, Nazli, et al.
Publicado: (2017)

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41
por: Sanders, Rogier W, et al.
Publicado: (2004)

The large extracellular loop of CD63 interacts with gp41 of HIV-1 and is essential for establishing the virological synapse
por: Ivanusic, Daniel, et al.
Publicado: (2021)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

Structural characterization and conformational dynamics of alpha-1 antitrypsin pathogenic variants causing alpha-1-antitrypsin deficiency
por: Shaik, Noor Ahmad, et al.
Publicado: (2022)

Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1
por: Pu, Jing, et al.
Publicado: (2021)

Assessing the protective efficacy of antibodies to the HIV gp41 region by active vaccination
por: Sharma, SK, et al.
Publicado: (2012)

Enhancing Exposure of HIV-1 Neutralization Epitopes through Mutations in gp41
por: Blish, Catherine A, et al.
Publicado: (2008)

Asymmetric Deactivation of HIV-1 gp41 following Fusion Inhibitor Binding
por: Kahle, Kristen M., et al.
Publicado: (2009)

HIV-1 Fusion Is Blocked through Binding of GB Virus C E2D Peptides to the HIV-1 gp41 Disulfide Loop
por: Eissmann, Kristin, et al.
Publicado: (2013)

Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike
por: Lee, Jeong Hyun, et al.
Publicado: (2015)

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions
por: Qi, Qianqian, et al.
Publicado: (2017)

Alpha 1-antitrypsin and survival in hepatocellular carcinoma.
por: Tzonou, A., et al.
Publicado: (1990)

alpha1-Antitrypsin deficiency and hepatocellular cancer.
por: Kew, M. C., et al.
Publicado: (1978)

The prevalence of alpha-1 antitrypsin deficiency in Ireland
por: Carroll, Tomás P, et al.
Publicado: (2011)

Alpha 1-antitrypsin retention in an ectopic liver
por: Dettmer, Matthias, et al.
Publicado: (2011)

Polymorphism of alpha-1-antitrypsin in hematological malignancies
por: Topic, Aleksandra, et al.
Publicado: (2009)

Alpha-1-Antitrypsin in Pathogenesis of Hepatocellular Carcinoma
por: Topic, Aleksandra, et al.
Publicado: (2012)

Alpha‐1‐antitrypsin in cell and organ transplantation
por: Berger, Mel, et al.
Publicado: (2018)

Alpha-1 Antitrypsin Deficiency: The Learning Goes On
por: Stockley, Robert. A.
Publicado: (2020)

Monocytes and Macrophages in Alpha-1 Antitrypsin Deficiency
por: Belchamber, Kylie B R, et al.
Publicado: (2020)

Alpha-1 Antitrypsin Deficiency: Home Therapy
por: Annunziata, Anna, et al.
Publicado: (2021)

Correction: HIV-1 Fusion Is Blocked through Binding of GB Virus C E2D Peptides to the HIV-1 gp41 Disulfide Loop
por: Eissmann, Kristin, et al.
Publicado: (2014)

Characterization of CD8 T Cell-Mediated Mutations in the Immunodominant Epitope GP33-41 of Lymphocytic Choriomeningitis Virus
por: Smyth, Mark, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n4591ui707qqb6dot167vegcqc